Vascular risk factors (e.g. hypertension, dyslipidemia and diabetes) are well known risk factors for Alzheimer' disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
34/100
Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The potential of brain imaging has grown rapidly with new modalities, hybrid combinations of existing modalities, and novel metabolic tracers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Tau pathology is a major age-related event in Down syndrome with Alzheimer’s disease (DS-AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The goals of this study were to compare the early diagnostic utility of Alzheimer disease biomarkers in the CSF with those in brain MRI in conditions found in our clinical practice, and to ascertain the diagnostic accuracy of both techniques used together. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Agreement between Syngo.via and MIMneuro varied by region. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Positron emission tomography (PET) provides an in vivo molecular marker for various diseases, including Alzheimer's disease and related dementias (ADRD). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
One of the most challenging tasks for neurologists is the early diagnosis of Alzheimer’s disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Flortaucipir (FTP) PET imaging was developed to quantify tau burden in tauopathies such as Alzheimer’s disease (AD) and to distinguish AD from other dementias, including frontotemporal lobar degeneration (FTLD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A pilot study was performed to test the ability of MR to evaluate the brain lucencies shown by CT in Alzheimer disease patients and in normal control subjects. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Down Syndrome (DS) is the most common of the chromosomal disorders and manifests abnormalities in several organ systems. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cortical posterior hypometabolism on PET imaging with 18 F-FDG (FDG-PET), and altered levels of Aß 1-42 peptide, total Tau (tTau) and phosphorylated Tau (pTau) proteins in cerebrospinal fluid (CSF) are established diagnostic biomarkers in Alzheimer's disease (AD). 4 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 15,346 White, 829 Latino, 637 Black/African American, and 321 Asian individuals, 51% were female, mean age was 75.7 years, 535 (3.8%) resided in ADI 91 to 100 decile, and 61.6% were amyloid PET positive. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Die Frühphasen- & R1-Bilder korrelierten signifikant in allen Gruppen (Gesunde: r=0,68-0,84; AD: r=0,81-0,9; PSP-RS: r=0,81-0,86; FTD: r=0,76-0,82). 5 key findings →
Participants: 26 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mild Cognitive Impairment (MCI) is marked by a measurable decline in cognitive function that exceeds typical age-related changes but does not yet qualify as dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
White matter hyperintensity (WMH) is the core imaging hallmark of cerebral small vessel disease (CSVD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia arising in patients with Parkinson disease or parkinsonian neurodegeneration comprises a heterogeneous neuropathology. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinical indications of amyloid imaging in atypical dementia remain unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To determine the relationship between regional brain edema caused by anti-amyloid monoclonal antibody therapy (ARIA-E) and the degree of regional β-amyloid (Aβ) positron emission tomography (PET) signal reduction. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or older in the United States. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
PET imaging demonstrated high cortical brain uptake of all 3 radiotracers in Tg-ArcSwe mice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sowohl in der Tau- als auch in der Amyloid-PET-Bildgebung zeigte die Quantifizierung eine gute bis exzellente Vorhersage der visuellen Beurteilung (Tau: AUC=0,86, p<0,0001; Amyloid: AUC=0,99, p<0,0001). 5 key findings →
Participants: 201 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
32/100
Using approximately 5,000 ADNI MRI images, the model achieved 97.67% accuracy, 97.73% precision, 97.67% recall, and 97.65% F1-score, with AUC values near 1.00. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Magnetic Resonance Imaging (MRI) provides detailed structural information, while functional MRI (fMRI) captures temporal brain activity. 2 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The use of statistical physics models to investigate real-world networks and reveal their underlying dynamics has shown promising results and acquired increasing attention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 2,885 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases
- Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000
- Life course, genetic, and neuropathological associations with brain age in the 1946 British Birth Cohort: a population-based study
- The development and validation of tau PET tracers: current status and future directions
- Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer's Disease: A Systematic Review
- Resting-state functional connectivity in neuropsychiatric disorders
- Brain-wide glymphatic enhancement and clearance in humans assessed with MRI
- Intracranial hypotension: clinical presentation, imaging findings, and imaging-guided therapy
- Cerebral amyloid angiopathy in the elderly
- Regional brain abnormalities associated with long-term heavy cannabis use
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →